

REMARKS/ARGUMENTS

Reconsideration of this application is requested. Claims 35 and 38 are in the case.

I. THE INTERVIEW

At the outset, the undersigned wishes to thank the Examiner (Mr. Thomas) for kindly agreeing to conduct an interview in this case. The interview was held on August 18, 2011, and the courtesies extended by the Examiner were most appreciated. The substance of the interview will be clear from the comments presented below.

II. THE OBVIOUSNESS REJECTION

Claims 35 and 37-38 are rejected under 35 U.S.C. §103(a) as allegedly unpatentable over Tinti *et al.* (EP 0 443 996 A1; 1991) in view of Salvioli *et al.* ("L-acetylcarnitine treatment of mental decline in the elderly"; 1994; *Drugs Under Experimental and Clinical Research*; 20(4): 169-76; PubMed abstract; PMID: 7813389); and Bach *et al.* ("Medium-chain triglycerides: an update"; 1982; *Am. J. Clin. Nutri.* 36:950-962).

During the interview, following a discussion of the cited prior art, the outstanding obviousness rejection and the pending claims, agreement was reached that consideration would be given to withdrawing the outstanding obviousness rejection if claim 35 is amended to remove the medium chain length triglycerides (MCT's). It was agreed that Bach does not disclose or suggest anything other than MCT's.

In light of the outcome of the interview, and without conceding to the rejection, claim 35 has been amended to delete, without prejudice, the medium chain triglycerides. Applicant reserves the right to pursue cancelled subject matter in a separate continuing case.

It is believed that the invention as now claimed is not suggested by the cited prior art. Withdrawal of the obviousness rejection is respectfully requested.

Favorable action is awaited.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /Leonard C. Mitchard/
Leonard C. Mitchard
Reg. No. 29,009

LCM:iff
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100